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ABSTRACT: An important objective of cancer nanomedicine is to improve the delivery
efficacy of functional agents to solid tumors for effective cancer imaging and therapy.
Stimulus-responsive nanoplatforms can target and regulate the tumor microenvironment
(TME) for the optimization of cancer theranostics. Here, we developed magnetic
manganese oxide sweetgum-ball nanospheres (MMOSs) with large mesopores as tools for
improved cancer theranostics. MMOSs contain magnetic iron oxide nanoparticles and
mesoporous manganese oxide (MnO2) nanosheets, which are assembled into gumball-like
structures on magnetic iron oxides. The large mesopores of MMOSs are suited for cargo
loading with chlorin e6 (Ce6) and doxorubicin (DOX), thus producing so-called CD@
MMOSs. The core of magnetic iron oxides could achieve magnetic targeting of tumors
under a magnetic field (0.25 mT), and the targeted CD@MMOSs may decompose under
TME conditions, thereby releasing loaded cargo molecules and reacting with endogenous
hydrogen peroxide (H2O2) to generate oxygen (O2) and manganese (II) ions (Mn
2+).
Investigation in vivo in tumor-bearing mice models showed that the CD@MMOS
nanoplatforms achieved TME-responsive cargo release, which might be applied in chemotherapy and photodynamic therapy. A
remarkable in vivo synergy of diagnostic and therapeutic functionalities was achieved by the decomposition of CD@MMOSs
and coadministration with chemo-photodynamic therapy of tumors using the magnetic targeting mechanism. Thus, the result of
this study demonstrates the feasibility of smart nanotheranostics to achieve tumor-specific enhanced combination therapy.
KEYWORDS: Magnetic manganese oxide, Tumor microenvironments, Cancer nanotheranostics, Triggered cargo release,
Nanomedicine
1. INTRODUCTION
An important objective of cancer nanomedicine is to improve
the effective delivery of functional agents to solid tumors,
thereby increasing the efficacy of cancer imaging and
therapy.1,2 Stimuli-responsive nanoplatforms can specifically
target the tumor microenvironment (TME) and adjust them to
facilitate cancer theranostics.3 Currently, active and passive
targeting mechanisms are mainly two mechanisms to evaluate
the nanoplatforms for delivery.4,5 Nanoparticles sized 50−200
nm would enable prolonged circulation in blood and efficient
delivery to tumors through the passive targeting mechanism
(i.e., enhanced permeability and retention (EPR) effect).6,7
Approaches utilizing physical forces, such as magnetic fields,
have been employed to efficiently deliver nanocarriers to
tumors.8,9 Such magnetic interactions using magnetic iron
oxide nanoparticles occur independently of TME and could
regulate TME conditions.10,11 Importantly, magnetic targeting
is in use in clinical trials for both cancer diagnosis and
treatment.12 In contrast, nanoparticles sized between 5 and 10
nm have better intratumoral penetration efficiency than larger
ones.13 Therefore, to balance targeting efficacy and tumor
penetration to achieve optimal therapeutic effects, the ideal
nanoplatforms should be located in the range of 50−200 nm
and stable during circulation in the blood, and once entering
the tumor region, they can break up into small fragments
because of the TME conditions, thus enabling enhanced
penetration and accelerated cargo release at the target site.14,15
TME has several physiological characteristics, including low
pH values, hypoxia, and high levels of glutathione (GSH),
reactive oxidative species (ROS), and certain enzymes.16
Manganese oxide (MnO2) has recently been observed to be
able to detect and respond to the TME17 as TME-responsive
theranostic agents.14,18 Under TME conditions, MnO2 reacts
with physiological characteristics (H+, GSH, and H2O2) and
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then releases Mn2+ ions, which enables T1-weighted magnetic
resonance imaging (T1-MRI) and are rapidly excreted by
kidneys.19−23 Oxygen, which is also released during MnO2
decomposition, may enable ultrasound (US) imaging and also
decrease tumor hypoxia levels.24 Such effects may enhance the
efficacy of cancer therapies that oxygen plays essential
roles,20,25 such as radiotherapy and photodynamic therapy
(PDT), and Fenton-like chemodynamic therapy.18,26,27 Most
of the MnO2 nanostructures described previously were sheet-
like structures or composites.19,20,28,29 These nanostructures
may have the limitation for the effective loading and controlled
release of cargos. The activities of mesoporous nanospheres
with large pore sizes have been demonstrated to achieve
precisely controlled release of the cargos. However, applica-
tions of mesoporous magnetic MnO2 with a gum-ball bionic
architecture as a smart intelligent theranostic platform have not
yet been reported.
Herein, we develop magnetic MnO2 bionic structures with
large mesopores composed of magnetic iron oxide nano-
particles and mesoporous MnO2 nanosheets assembled in
gumball-like nanospheres (Scheme 1). The magnetic man-
ganese oxide sweetgum-ball nanospheres (MMOSs) with large
mesopores turned out to be ideal for cargo loading. Chlorin e6
(Ce6) and doxorubicin (DOX) were effectively loaded,
yielding CD@MMOSs (Scheme 1a). After intravenous
administration of CD@MMOSs into tumor-bearing mice, the
nanoplatforms undergo efficient passive tumor homing, and
the use of magnetic fields leads to more effective tumor
targeting (Scheme 1b). Under TME conditions, the fast
decomposition of MnO2 nanostructures prompts the release of
the loaded cargos for chemotherapy and PDT while
simultaneously facilitating MR, US, and fluorescence imaging
(Scheme 1b). Synergistic in vivo therapeutic effects were
achieved by combining chemotherapy and PDT with CD@
MMOSs (Scheme 1b). The present work illustrates the great
potential of targeting the TME with smart nanotheranostics to
achieve tumor-specific enhanced combination therapy.
2. EXPERIMENTAL SECTION
2.1. Synthesis of Magnetic Manganese Oxide Sweetgum-
Ball Nanospheres (MMOSs). The magnetic Fe3O4 nanoparticles
were synthesized based on the coprecipitation method.30 After 3 h,
the black precipitates were collected by magnetic decantation. Finally,
oleic acid (OA) was added to obtain OA-protected Fe3O4 (OA-
Fe3O4). Then KMnO4 solution was reacted with OA-Fe3O4.
31,32
Afterward, the as-synthesized products were calcined at 250 °C.
2.2. Simulation of Tumor Microenvironment Stimulated
Decomposition of MMOSs. To investigate the degradation,
MMOSs were incubated in media at 37 °C: (a) pH 5.4, (b) pH
7.4, and (c) pH 5.4 with 1.0 mM H2O2. The color changes and
degradation of MMOSs were captured and determined. The
generation of Mn2+ was measured by T1-MRI (9.4 T). The generation
of O2 was evaluated using [Ru(dpp)3]Cl2 as the O2 probe. For
control, the same concentrations of [Ru(dpp)3]Cl2 and H2O2 were
kept in air. In sealed vials, 0.1 μM [Ru(dpp)3]Cl2 was put in 2.0 mL
plastic tubes to avoid direct contact with H2O2 solution with or
without MMOSs. After 12 h, the fluorescence of probes was measured
(ex/em: 455/615 nm) to determine the O2 generation.
2.3. Loading and Stability of Ce6 and DOX in MMOSs (CD@
MMOSs). For loading of DOX and Ce6 in MMOSs, DOX and Ce6
(mass ratio of 1:1) were mixed with various concentrations of
MMOSs (the ratio of MMOSs/DOX and Ce6 from 1 to 1/4) at room
temperature for 6 h.33 Loading capacity (LC) was calculated using eq
1:
= ×LC%
weight of loading cargo
weight of MMOSs
100
(1)
The release was evaluated at 37 °C: (a) pH 5.4, (b) pH 7.4, and
(c) pH 5.4 containing 1 mM H2O2. The absorbance of cargos was
measured to evaluate the release.
2.4. Detection of Singlet Oxygen (1O2) in Solution. Briefly,
CD@MMOSs (0.1 mg/mL) were mixed with ABDA (100.0 μL, 1.0
mg/mL) in which the solution with or without H2O2 (1 mM) was
Scheme 1. (a) Schematic of the Effective MMOS-Based Cargo Delivery System. (b) Precisely Controlled Smart Nanodelivery
of Theranostic Agents That Act To Regulate the Tumor Microenvironment
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irradiated by a 670 nm laser (100 mW/cm2) for 5 min. The
absorbance of ABDA at 378 nm was measured.34
2.5. Cell Uptake and Cytotoxicity. The cytotoxicity of MMOSs
was evaluated using a standard MTT assay. Human glioma cells
(U87MG) were seeded and incubated for 24 h. Then MMOSs (0−
500 μg/mL) were added to incubate for 24 h. The MTT assay was
then performed to monitor the absorbance of each well at 570 nm.
For confocal fluorescence imaging, after incubation of U87MG
cells and CD@MMOSs (Ce6: 2.0 μg/mL, DOX: 2.5 μg/mL) for
different times, the cells were stained with Hoechst 33342. Images
were captured using a laser scanning confocal fluorescence micro-
scope (Leica Microsystems, Germany).
2.6. Prussian Blue Staining for Cells Incubated with
MMOSs. U87MG cells (105/well) and MMOSs (0.1 mg/mL) were
incubated for 12 h. For comparison, the magnetic field (0.25 mT, 30
min) was located to study the in vitro uptake effect of MMOSs. After
washing with PBS, Prussian blue staining followed a previously
published protocol.35
2.7. 1O2 Generation in Cells. To monitor
1O2 generation in live
cells, U87MG cells and CD@MMOSs (Ce6: 2.0 μg/mL, DOX: 2.5
μg/mL) were incubated for 24 h. 1 μM SOSG was added to the fresh
medium. Then 670 nm irradiation was applied to cells for 5 min (100
mW/cm2). Fluorescence images were acquired on an Olympus
FV1200 laser scanning confocal microscope using an FITC filter.
2.8. In Vitro Therapy. U87MG cells (104/well) were incubated
with free DOX, DOX-loaded MMOSs (D@MMOSs), free Ce6, Ce6-
loaded MMOSs (C@MMOSs), and CD@MMOSs. The solution
containing Ce6 was irradiated by a 670 nm laser (100 mW/cm2, 5
min). Cell viabilities were determined by the standard MTT assay.
2.9. Clearance Behaviors and Biodistribution In Vivo. Female
BALB/c mice (∼20 g) were purchased from the Animal Care and Use
Committee of Xiamen University. Mice bearing tumors were prepared
by subcutaneously injecting 107 U87MG cells into the back of the
hind leg. All the animal experiments were in accordance with the
Guidelines of the Regional Ethics Committee for Animal Experiments
and the Care Regulations approved by the Institutional Animal Care
and Use Committee of Xiamen University.
To investigate clearance behaviors and biodistribution of MMOSs,
tumor-bearing mice (n = 3) were intravenously injected with MMOSs
(2.0 mg/kg) when the tumor reached 60 mm3. Blood was gained from
the orbital venous plexus at the post-injection time point. For
biodistribution, mice were euthanized at the same time points. Then
the major organs were collected, weighed, and digested with HNO3-
H2O2 solution. The Mn content in each tissue and blood were
measured by inductively coupled plasma mass spectrometry (ICP-
MS).
2.10. Tumor Microenvironment Triggered MMOS Decom-
position. To study the decomposition of MMOSs triggered by the
tumor microenvironment (H, H2O2), MMOSs (0.5 mg/mL, 20 μL)
and H2O (20 μL) were injected intratumorally and the muscles near
the tumors, respectively. MR imaging was performed at different post-
injection time points to monitor the decomposition of the MMOSs.
2.11. In Vivo Imaging. When the tumor reached 120 mm3,
tumor-bearing mice (n = 3) were intravenously injected with CD@
MMOSs (10 mg/kg) for imaging. MR imaging (T1 or T2) was
conducted on a 9.4 T clinical MRI small animal MRI system (Bruker,
Germany) at 2, 4, and 24 h post-injection time points. T1- and T2-
weighted MRI were measured using a spin echo multiple slice
Figure 1. Characterization of magnetic manganese oxide sweetgum-balls (MMOSs). (a) TEM image of MMOSs. (b) Element mapping images
captured from TEM. (c) SEM image (scale bar: 200 nm). (d) Elemental analysis by SEM. (e) Surface area analysis and pore size distribution
(inset). (f) Photograph indicating magnetic capture of MMOSs. (g) Room-temperature magnetic hysteresis loops of Fe3O4 and MMOSs. (h)
Phantom study of MMOSs at 9.4 T.
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sequence, and the parameters were the following: T1 imaging: TR =
1000.0 ms; TE = 8.5 ms; matrix = 256 × 256; multislice spin−echo
sequence with a field of view of 40 × 40 mm, and T2 imaging: TR =
2500.0 ms; TE = 33.0 ms; matrix = 256 × 256; multislice spin−echo
sequence with a field of view of 40 × 40 mm. Fluorescence imaging
was conducted at 2, 8, and 24 h post-injection time points using an
IVIS Lumina II in vivo imaging system. At the 24 h time point, tumors
and major organs were collected for acquisition of fluorescence
signals.
2.12. In Vivo Cancer Therapy. When the tumor reached about
∼60 mm3, tumor-bearing mice were divided randomly into 10 groups
(n = 5/group): (1) saline (PBS), (2) MMOSs + magnet (MMOSs +
M), (3) free Ce6 and DOX (CD), (4) free Ce6 and DOX + laser
(CD + L), (5) D@MMOSs + magnet (D@MMOSs + M), (6) C@
MMOSs + magnet + laser (C@MMOSs + M + L), (7) CD@
MMOSs, (8) CD@MMOSs + magnet (CD@MMOS + M), (9)
CD@MMOSs + laser (CD@MMOS + L), (10) CD@MMOSs +
magnet + laser (CD@MMOSs + M + L). The injection doses were
fixed to be 2.0 (MMOSs), 3.5 (Ce6), and 4.5 mg/kg (DOX). The
magnet (0.25 mT) was bound on the tumor sites for 30 min after
injecting agents to guide the accumulation of nanoparticles at the
tumor.36 A laser (670 nm, 100 mW/cm2, 5 min) was used on the
tumor areas at 8 h of post-injection. Tumor sizes and body weights
were monitored every 2 days. The tumor sizes, body weights, and
tumor volumes were calculated using the following: volume = width2
× length/2. One mouse randomly chosen from each group was
euthanized, and the excised tumors and major organs were collected
for standard H&E staining. The remaining mice were monitored for
long-term survival.
2.13. Serum Chemistry Analysis. Female BALB/c mice were
intravenously injected with CD@MMOSs (10 mg/kg). Blood
samples were collected for serum chemistry analysis at days 3 and 7
post-injection. Alanine transaminase, aspartate transaminase, creatine
kinase, creatinine, and blood urea nitrogen were measured in serum
using an Auto Biochemistry analyzer (Mindray, BS-220).
2.14. Statistical Analysis. All results were presented as mean ±
standard deviation (SD). Comparison of the data was conducted with
Student’s t test, and statistical significance was set at p < 0.05 (*P <
0.05, **P < 0.01, and ***P < 0.001).
3. RESULTS
3.1. Synthesis and Characterization. Magnetic iron
oxide (Fe3O4) nanoparticles were successfully prepared using a
coprecipitation method with minor modifications.30 After
separation from the reaction mixture, oleic acid was added
and sonicated to obtain oleic acid modified Fe3O4 (OA-
Fe3O4). Magnetic manganese oxide (MMO) was synthesized
via a facile microemulsion method.31,32 Transmission electron
microscopy (TEM) imaging showed that the as-synthesized
MMO consisted of urchin-like structures with a size of 130.4 ±
9.9 nm (Figure 1a). Elemental mapping analysis clearly
revealed that MMO contained Mn, O, and Fe, which were
evenly distributed across its structures (Figure 1b). Scanning
electron microscopy (SEM) imaging showed that the MMO
had a similar morphology and pore structure to sweetgum balls
(Figure 1c, Figure S1). Our previous study revealed the
formation of the typical structure.31 Its size and morphology
were evaluated by increasing the reaction time. The initially
Figure 2. In vitro drug release and combination therapy. (a) UV−visible spectra of free Ce6, free DOX, MMOSs, and CD@MMOSs. (b) Ce6 and
DOX loading weight ratios in CD@MMOSs at different feeding/drug MMOS ratios. (c) Percentages of released Ce6 and DOX over time. (d)
Confocal images of U87MG cells treated with CD@MMOSs at different time points. The blue, green, and red stains represent Hoechst, Ce6, and
DOX fluorescence, respectively (scale bar: 10 μm). (e) Comparison of cytotoxicity following chemo (free DOX, D@MMOSs, and CD@MMOSs)
and chemo-photodynamic combined treatments (CD@MMOSs + laser). (f) Change in ABDA absorbance MMOSs reflecting singlet oxygen
generation. (g) In vitro PDT treatment of U87MG cells by free Ce6 or C@MMOSs under 670 nm laser irradiation (100 mW/cm2, 5 min).
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formed nanosheets self-assembled to form stable sweetgum-
ball-like structures.
The X-ray diffraction (XRD) patterns and X-ray photo-
electron spectra (XPS) were further applied to confirm the
presence of MnO2 NP (Figure S2a,b). The observed
characterized peaks at about 24 (2θ), 37 (2θ), and 67° (2θ)
and two characteristic peaks located at 642.4 (Mn 2p3/2) and
654.0 eV (Mn 2p1/2) were in full support of the formation of
MnO2. Energy dispersive X-ray spectroscopy (EDS) spectra
confirmed Mn, O, Fe, K, and C exist in the MMO structures,
and the atomic ratio of Mn/Fe was 10/1 (Figure 1d). The
surface area and pore size distribution of MMOSs were 121 m2
g−1 and 23.3 nm, respectively (Figure 1e). The MMOSs could
be easily manipulated under an external magnetic field (Figure
1f), and its saturation magnetization was about 24.5 emu g−1
(Figure 1g). Additionally, the detected transverse relaxivity (r2)
was 215 mM−1 s−1 (9.4 T) (Figure 1h), which was very close
to that of the Fe3O4 nanoparticles (230 mM
−1 s−1, 9.4 T)
(Figure S3).
The unique gumball morphology with large porous
structures allows MMOSs for cargo encapsulation. Using a
double-interaction mechanism,33 doxorubicin (DOX), a
common anticancer drug, and chlorin e6 (Ce6), a typical
photosensitizer, were successfully coloaded into the MMOSs,
resulting in very high cargo loading contents. Characteristic
peaks of DOX and Ce6 could be detected with ease in the
absorbance spectrum of the CD@MMOSs. Of note, an
obvious red shift in the absorbance between 670 and 710
nm was presumably caused by the interaction between Ce6
and MMOSs (Figure 2a). The loading ratio increased with
higher initial weight ratios of cargo molecules and MMOSs
(Figure 2b). When the initial cargo/MMOS weight ratio was
set at 4, the loading capacity (LC) reached 419.1% (CD@
MMOSs). After loading cargos, the surface charge of MMOSs
increased from −38.06 to −33.07 mV, indicating that the
cargos were successfully loaded (Figure S4a). The CD@
MMOSs showed excellent stability in media, such as phosphate
buffer solution (PBS), DMEM medium, and serum (Figure
S4b).
After successful loading, the controlled release of the cargos
from the CD@MMOSs was evaluated by recording the
absorbances of DOX (480) and Ce6 (640 nm) in media.
Figure 3. Tumor-specific detection by T1-weighted MR imaging and ultrasound imaging by MMOSs. (a) Phantom study of MMOSs in 9.4 T MR
instrument at different pH values. (b) Homemade setup for the detection of O2. (c) Fluorescence spectra of [Ru(dpp)3]Cl2 of MnO2 with or
without H2O2. (d) T1-MRI images of U87MG tumor-bearing mice before and after local injection of MMOSs within normal and tumor
subcutaneous tissues. (e) T1-MRI signal strength before and after injection of MMOSs and H2O. (f) Ultrasound imaging showing the generation of
O2 in tumors after locally injected MMOSs. (g) Relative echo intensity in U87MG tumor-bearing mice after local injection of MMOSs within
tumor-containing subcutaneous tissues, indicating O2 generation.
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Stability and controlled release are keys to promote effective
chemotherapy with minor side effects as well as to facilitate
PDT. As shown in Figure 2c, both the cargos reached the
release balance after 8 h of incubation at pH 7.4 in PBS and the
released amounts of DOX and Ce6 were less than 26.1 and
20.8% after a 24 h incubation, indicating relatively high
stability of CD@MMOSs both in normal physiological
environments and in the circulation environments. However,
large quantities, that is, 56.1% of DOX and 43.8% of Ce6, were
released from CD@MMOSs at pH 5.4 after 8 h, and 62.8% of
DOX and 44.8% of Ce6 after 24 h of incubation. More
interestingly, when the incubation environment at pH 5.4
contained hydrogen peroxide (H2O2, 1 mM), the loaded
cargos were released more rapidly than in environments
without H2O2 (Figure 2c).
3.2. In Vitro Experiments. Intracellular cargo release
behaviors were investigated using U87MG cancer cells
incubated with CD@MMOSs.37 In the initial incubation
period (1−2 h), the weak fluorescence signals of DOX and
Ce6 in the cytoplasm were indicative of endocytosis of CD@
MMOSs (Figure 2d). Prolonging the incubation time clearly
increased the nuclear fluorescence signals of DOX, demon-
strating both the successful release of DOX from CD@
MMOSs and delivery to the nuclei (Figure 2d). The MMOSs
did not induce cellular toxicity when applied in doses up to
500 μg/mL (Figure S5a),38 and there was no significant
cytotoxicity in H2O2 only and Ce6 + H2O2 (Figure S5b);
however, the released DOX molecules from CD@MMOSs
significantly inhibited cell proliferation (Figure 2e), and the
half-maximal inhibitory concentration (IC50) of CD@MMOSs
was 3.0 μg/mL. The released Ce6 was tested for its
photosensitizing effect during active PDT. Singlet oxygen
(1O2) generation efficacy in solution using 9,10-anthracene-
diyl-bis(methylene)dimalonic acid (ABDA) as the probe was
measured by monitoring the change in absorbance at 378
nm.34 ABDA molecules were assumed to react with singlet
oxygen to decrease the absorbance. In all cases, the absorbance
of ABDA decreased, indicating the generation of 1O2 (Figure
2f). Additionally, in a simulated tumor microenvironment (pH
5.4, 1 mM H2O2), the absorbance of ABDA decreased quickly,
also indicating 1O2 generation (Figure 2f). Finally,
1O2 was
generated efficiently inside the cells incubated with C@
MMOSs and CD@MMOSs under laser irradiation using
Singlet Oxygen Sensor Green (SOSG) as a sensor (Figure S6).
These results suggest that the MnO2 carriers could enhance
the PDT process. Indeed, the PDT process induced significant
cell death (Figure 2g). More importantly, the combination of
chemotherapy and PDT induced more significant cell
inhibition, and IC50 of CD@MMOSs decreased by 3-fold
(1.0 μg/mL) compared to that of chemotherapy alone (Figure
2g).
3.3. In Vivo Imaging. Previous investigations have
revealed that, under TME conditions, MnO2 nanosheets
reacted with H+ and H2O2.
19,20,39,40 Hence, we carefully
investigated the catalytic performance of MMOSs. The size
and morphology of MMOSs in PBS (pH values 7.4 and 5.4)
were investigated (Figure S7a,b). A color change was clearly
observed, indicating the breakup of MMOSs in the acidic
environment; the speed of the color change increased when
H2O2 was present in the acidic environment (Figure S8). To
validate the degradation of the MMOSs, the incubation
mixtures were analyzed by TEM at 0 and 2 h. Obviously, the
particle size changed from large MMOSs to many smaller
fragments (Figure S9), demonstrating the degradation of
MMOSs in simulated TME conditions. The color changes
were also visible in the absorbance of solutions (Figure S9a).
Furthermore, the changes of MRI signals reflected the release
of Mn2+ from the decomposition process of MMOSs (Figure
S9b−d). The in vitro T1-MRI performance of MMOSs was
investigated in simulated normal and tumorous conditions next
(Figure 3a). With increasing concentrations of Mn, the T1-
MRI signal in modified PBS (pH 5.4, H2O2 1 mM) had faster
enhancement than that in PBS (pH 7.4). Due to the released
Mn2+, the longitudinal relaxivity (r1) of the MMOSs increased
markedly to 1.8 mM−1 s−1 (9.4 T) under simulated tumorous
conditions (pH 5.4, H2O2 1 mM) (Figure 3a).
In the presence of H2O2, MMOSs catalyzed 3,3,5,5-
tetramethylbenzidine (TMB) and yielded a blue color (Figure
S10), confirming that MMOSs have peroxidase activity.41
Under TME conditions and paralleling the generation of Mn2+,
bubbles rapidly developed in sealed tubes (Figure S11). To
determine whether the generated bubbles consisted of oxygen
(O2), custom-made sealed vials were used to measure the
dissolved O2 with an O2 nanoprobe [Ru(dpp)3]Cl2 during
MMOS decomposition (Figure 3b).42 After 24 h, the
fluorescence of the oxygen probes decreased by 37.6%,
indicating that O2 was generated efficiently in the MMOS/
H2O2 mixture under acidic conditions (Figure 3c). In vitro
studies also confirmed that O2 generation in tumor cells
decreased the level of fluorescence of [Ru(dpp)3]Cl2 after
incubation with MMOSs and tumor cell lines (Figure S12). To
further confirm the decomposition, we injected MMOSs
intratumorally and the injection site was very close to the
skin. At 1 h of post-injection, a distinct brown-black color
could be observed at the injection site of tumors and
completely disappeared after 24 h of post-injection (Figure
S13).
To evaluate whether microenvironmental regulation by
tumors facilitates in vivo tumor imaging, a U87MG tumor
xenograft model was used. MMOSs in saline were injected
directly into tumor tissues (Figure 3d; ellipsoid circles) and
also in normal subcutaneous tissues (red circles) for
comparison. Near-tumor positive contrast-enhancement
around the injection sites developed over time in T1-MRI
and decreased gradually as MMOSs were used up. Conversely,
no positive contrast-enhancement was observed after injections
at normal nontumor sites (Figure 3d). The T1-weighted MRI
signal increased by 2.0-fold after the decomposition of the
MMOSs (Figure 3e). US images showed a similar trend.
Around the injection sites in tumors (Figure 3f; yellow
labeling), clear enhancement of US contrast confirmed the
generation of O2 (Figure 3f,g). Furthermore, pimonidazole-
based hypoxia staining was evaluated. The hypoxic areas were
stained with hypoxia inducible factor 1 alpha (HIF-1α)
(green). Compared with the control group, green fluorescence
significantly decreased in the group of CD@MMOSs,
indicating that the generation of O2 could relieve the tumor
hypoxia (Figure S15).43 Thus, the decomposition of MMOSs
can affect the tumor microenvironment by quick Mn2+ release
and generation of O2, as well as achieve cargo release, with
facilitating effects on, for example, chemotherapy and photo-
therapy.44
Following the demonstration of local decomposition and
delivery of therapeutics in the in vitro experiments, tumor
accumulation of the MMOSs was evaluated in response to
systemic administration to U87MG tumor-bearing mice. Prior
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to this in vivo test, we investigated the effect between magnetic
field and cellular uptake rates. Prussian blue (PB) staining of
cells produced more positive signals when a magnetic field was
employed (0.25 mT) (Figure S14a),35 as did tumor tissues,
confirming the enhanced delivery of MMOSs to the tumor
sites (Figure S14b). Next, we administered intravenously (iv)
CD@MMOSs (dose of MMOSs = 2.0 mg kg−1, Ce6 = 3.5 mg
kg−1, and DOX = 4.5 mg kg−1) to tumor-bearing nude mice,
while a magnet (0.25 mT) was maintained at the tumor site.
MRI images of the tumors that were obtained at 0, 2, 8, and 24
h of post-injection showed clearly increased T1 and decreased
T2 signals at tumor sites. At 8 h after administration, T1 and T2
signals reached their peaks and nadirs, respectively. In addition,
application of a magnetic field achieved significant contrast
enhancement (Figure 4a−c).45,46 The released Ce6 molecules
also produced clear fluorescence signals in the tumor regions,
most strongly at 8 h of post-injection, which indicates tumor
accumulation of the MMOSs (Figure 4d,e).47 Ex vivo imaging
showed that the biodistribution of MMOS at 24 h of post-
injection indicated a substantial uptake by tumors (Figure
S16).48 The clearance of MMOSs in U87MG tumor-bearing
mice showed that MMOSs had a long circulation (half-life 3.4
± 0.8 h; Figure 4f). Long circulation contributed to a high
accumulation of MMOSs in the U87MG tumor, reaching 13.7
± 1.0% injected dose per gram tissue (%ID/g) (Figure 4g).
3.4. In Vivo Combined Chemo-PDT Treatment.
Following the selective accumulation of CD@MMOSs in
tumors, the in vivo therapeutic efficacy was assessed. When the
tumor size reached 60 mm3, mice were randomly allocated to
10 groups that received different treatments: saline (group 1,
PBS), MMOSs + magnetic field (group 2, MMOSs + M), free
Ce6 and DOX (group 3, CD), free Ce6 and DOX + laser
(group 4, CD + L), D@MMOSs + magnetic field (group 5,
D@MMOSs + M), C@MMOSs + magnetic field + laser
Figure 4. In vivo imaging with CD@MMOSs. (a) In vivo T1/T2-MRI images of mice taken at different time points after iv injection of MMOSs in
the presence or absence of a magnetic field (0.25 mT). (b) Quantification analysis of T1-MRI signal change in tumors based on region of interest
(ROI) analysis on images from panel (a). (c) Quantification analysis of T2-MRI signal change in tumors based on ROI analysis on images from
panel (a). (d) In vivo fluorescence images of mice taken at different time points after iv injection of MMOSs in the presence of a magnetic field. (e)
Quantification analysis of the tumor/muscle (T/M) ratio of fluorescence signal change in tumors based on ROI from panel (d). (f) Time course of
blood levels of MMOS levels following intravenous injection. The half-life time (t1/2) was calculated to be 3.4 ± 0.8 h. (g) Biodistribution of Mn (%
injected dose (ID) Mn per gram of tissues) in main tissues and tumors after intravenous administration of MMOSs.
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(group 6, C@MMOSs + M + L), CD@MMOSs (group 7),
CD@MMOSs + magnetic field (group 8, CD@MMOS + M),
CD@MMOSs + laser (group 9, CD@MMOSs + L), and
CD@MMOSs + magnetic field + laser (group 10, CD@
MMOSs + M + L). At the 8 h time point after iv
administration of different agents (MMOSs = 2.0 mg/kg,
Ce6 = 3.5 mg/kg, and DOX = 4.5 mg/kg), mice in groups 3, 6,
8, and 10 were exposed to a 670 nm laser irradiation (100
mW/cm2) for 5 min. Also, the magnetic field (0.25 mT) was
applied to the tumor regions. The results showed that all the
treatments induced tumor inhibition, with inhibition ratios of
23.5 (group 2), 21.9 (group 3), 39.9 (group 4), 46.4 (group 5),
76.0 (group 6), 54.7 (group 7), 92.9 (group 8), 96.6 (group 9),
and 98.5% (group 10) (Figure 5a). Specifically, MMOSs with
and without magnetic fields (groups 7 and 8, chemotherapy;
groups 9 and 10, combination therapy) showed clear
differences, suggesting that the combination of magnetic
targeting and EPR effect promotes more effective tumor
accumulation of nanoparticles and better antitumor efficiency
(Figure 5b). Especially, administration of MMOSs combined
with laser and magnetic targeting (group 10) exhibited highly
effective tumor growth inhibition, leading to nearly complete
remission at day 14 after treatment (Figure 5c, Figure S14). At
day 14, all mice were euthanized and tumors were harvested.
The average tumor volume in group 10 was 12.3 mm3, which
was much smaller than those in groups 9 (27.8) and 8 (65.7
mm3) (Figure 5d). Free Ce6 and DOX administered without
(group 3) and with laser irradiation (group 4) exhibited no
appreciable effects on tumor growth, indicating that the free
agents were not able to effectively accumulate in the tumor
area (Figure 5a). PDT alone (group 6) and chemotherapy
alone (group 5) led to partial tumor growth inhibition. In
sharp contrast, in response to PBS (group 1) and MMOS
treatment (group 2), tumors grew very quickly, leading to 15-
fold and 13-fold increases in tumor volume, respectively.
Importantly, our combination therapy with CD@MMOSs
under magnetic targeting and laser irradiation was obviously
more efficacious than a predicted additive effect (Figure 5e),
indicating the significant synergy of delivery of agents with
CD@MMOSs and PDT and chemotherapy. Throughout
therapy, the body weight, serum chemistry, and H&E-stained
images of major organs from the therapy groups at day 14
suggested that the CD@MMOSs did not induce toxic side
effects in mice (Figures S18−S20). Most importantly, the
treatment group 10 showed 80% survival at day 30; however,
in the control groups 1−3, all mice died by day 22 (Figure 5f).
4. CONCLUSIONS
In summary, magnetic manganese oxide sweetgum-ball
(MMOS) bionic structures with large mesopores were
Figure 5. In vivo combined chemo-PDT treatment with MMOSs. (a) Tumor growth curves of the different groups of mice after various treatments.
(b) Tumor growth curves of groups 8−10. (c) Tumor volumes of groups 8−10. (d) Representative digital photographs of the dissected tumors
from each group 14 days after treatment. (e) Characteristic images of H&E-stained tumor tissues collected from mice at day 14 after the different
treatments: group 1: PBS, group 2: MMOSs + M, group 3: CD, group 4: CD + L, group 5: D@MMOSs + M, group 6: C@MMOSs + M + L,
group 7: CD@MMOSs, group 8: CD@MMOSs + M, group 9: CD@MMOSs + L, and group 10: CD@MMOSs + M + L. (f) Kaplan−Meier
survival curves of mice in the different treatment groups.
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developed and tested in vitro and in vivo. The bionic structures
with large mesopores were shown to be well suited for the
delivery of therapeutic and other therapy-enhancing cargos.
Using a double-interaction mechanism, the chemotherapeutic
drugs and photosensitizers were successfully loaded with high
cargo loading. The loaded MMOSs can be controlled to deliver
their cargos specifically into tumor regions by applying external
magnetic fields. Under TME conditions, the MMOSs reacted
with tumor-related H2O2 and H
+, leading to their decom-
position and generation of oxygen and Mn2+ during the release
of the loaded cargo molecules. As a result, both the in vitro and
in vivo experiments demonstrated that the MMOSs are capable
of TME-stimulated cargo release for multimodal imaging and
of remarkable synergies with both diagnostic and therapeutic
actions, for example, when combined with chemo-photo-
dynamic therapy. The present research demonstrates that
TME-related control of smart nanotheranostic constructs can
enhance tumor-specific combination therapies.
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